Pfizer plans to ask U.S. regulators to grant emergency use authorization for a second booster of its COVID-19 vaccine, CEO Albert Bourla said March 11.
“Clearly there is a need in an environment of Omicron to boost the immune response,” Bourla said on CNBC’s “Squawk Box.”